A strategy for combating drug-resistant cancers

Many cancer therapies function by activating proteins like Caspase-3 (CASP3) that promote cell death. Several forms of cancer develop resistance to these drugs by down regulating CASP3 through an unknown mechanism. In the absence of CASP3, tumor cells produce another cell death promoting protein CASP7, but it is rendered inactive by the X-linked inhibitor of apoptosis protein (XIAP).

In this issue of the Journal of Clinical Investigation, Po-Huang Liang and colleagues at Academia Sinica identify a compound (I-Lys) that disrupts the interaction between CASP7 and XIAP. Release of CASP7 from this complex in drug activated cell death and reduced malignancies. Furthermore, no adverse side effects were observed in non- treated with the drug.

In the accompanying commentary, Gregory Gores from the Mayo Clinic explains that these results are promising for combatting drug resistant cancers, but more work needs to be done to establish if I-Lys will be safe and beneficial for human use.

More information: Targeting the XIAP/caspase-7 complex selectively kills caspase-3–deficient malignancies, J Clin Invest. 2013;123(9):3861–3875. DOI: 10.1172/JCI67951
Unshackling caspase-7 for cancer therapy, J Clin Invest. 2013;123(9):3706–3708. DOI: 10.1172/JCI71440

add to favorites email to friend print save as pdf

Related Stories

Targeting pancreatic cancer drug resistance

Jul 08, 2013

Pancreatic cancer is one of the most deadly and intractable forms of cancer, with a 5-year survival rate of only 6%. Novel therapies are urgently needed, as conventional and targeted approaches have not been successful and ...

Recommended for you

How does prostate cancer form?

46 minutes ago

Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate prostate cancer formation are poorly understood. Finding an enzyme that regulates this process ...

Low risk of malignancy for small complex adnexal masses

7 hours ago

(HealthDay)—For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.